Tempest Therapeutics (NASDAQ:TPST) Trading Down 1.6% – Here’s Why

Tempest Therapeutics, Inc. (NASDAQ:TPST)’s stock price was down 1.6% on Thursday . The stock traded as low as $1.24 and last traded at $1.25. Approximately 41,415 shares traded hands during trading, a decline of 65% from the average daily volume of 118,351 shares. The stock had previously closed at $1.27.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on TPST shares. Zacks Research lowered shares of Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen lowered Tempest Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Tempest Therapeutics Price Performance

The company has a market cap of $18.51 million, a PE ratio of -0.21 and a beta of -1.85. The stock has a 50 day simple moving average of $1.75 and a two-hundred day simple moving average of $2.32.

Tempest Therapeutics (NASDAQ:TPST) last announced its earnings results on Thursday, May 14th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25). As a group, equities analysts anticipate that Tempest Therapeutics, Inc. will post -1.34 EPS for the current fiscal year.

Insider Transactions at Tempest Therapeutics

In related news, CEO Matthew Angel purchased 231,482 shares of the company’s stock in a transaction that occurred on Tuesday, March 24th. The shares were purchased at an average price of $2.16 per share, for a total transaction of $500,001.12. Following the transaction, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.28% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP purchased a new stake in shares of Tempest Therapeutics during the fourth quarter worth approximately $33,000. Vanguard Group Inc. increased its stake in Tempest Therapeutics by 20.8% in the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after buying an additional 27,952 shares during the period. Finally, Sabby Management LLC purchased a new position in Tempest Therapeutics during the 4th quarter worth $513,000. 22.52% of the stock is currently owned by hedge funds and other institutional investors.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.